MAGEA1 and metastatic melanoma: As to MAGE antigens, Stockert et al reported that an autoantibody against MAGE-A1 was detected in only 3 of 234 cancer patients (24), which was a very low frequency compared with ours (48.4% in metastatic melanoma patients).